Preoperative red blood cell distribution width as an independent prognostic factor in metastatic renal cell carcinoma. 2022

Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
Department of Urology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China.

OBJECTIVE This study aimed to explore the prognostic value of preoperative red blood cell distribution width (RDW) in patients with metastatic renal cell carcinoma (mRCC). METHODS Clinicopathological data of 230 patients with mRCC treated at the First Affiliated Hospital of Chongqing Medical University and the Chinese PLA General Hospital from January 2008 to December 2018 were retrospectively analyzed. Patients were stratified according to the optimal cut-off value of RDW calculated using X-tile software. The prognostic value of RDW was analyzed using the Kaplan-Meier curve with log-rank test and univariate and multivariate Cox proportional hazards models. RESULTS A total of 230 patients were included. The optimal cut-off value of RDW obtained using X-tile software was 13.1%. The median Progression-free survival (PFS) and Overall survival (OS) of all populations were 12.06 months (IQR: 4.73-36.9) and 32.20 months (IQR: 13.73-69.46), respectively. Kaplan-Meier curves showed that patients with high RDW had worse PFS and OS than those with low RDW (median PFS of 9.7 months vs. 17.9 months, P = 0.002, and median OS of 27.8 months vs. 45.1 months, P = 0.012, respectively). Multivariate analysis showed that RDW was an independent risk factor for PFS (HR: 1.505; 95% CI: 1.111-2.037; P = 0.008) and OS (HR: 1.626; 95% CI: 1.164-2.272; P = 0.004) in mRCC after cytoreductive nephrectomy. CONCLUSIONS Preoperative RDW was independently associated with PFS and OS in patients with mRCC and may be a potential predictor of survival outcomes in mRCC.

UI MeSH Term Description Entries

Related Publications

Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
March 2019, Urologic oncology,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
July 2020, Clinical laboratory,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
April 2024, Blood science (Baltimore, Md.),
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
July 2017, Annals of translational medicine,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
June 2021, Clinical hematology international,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
June 2019, Anticancer research,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
December 2012, BJU international,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
March 2024, Experimental hematology,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
December 2021, Blood advances,
Zongjie Wei, and Fan Zhang, and Xin Ma, and Weiyang He, and Xin Gou, and Xu Zhang, and Yongpeng Xie
January 2022, Annals of translational medicine,
Copied contents to your clipboard!